Media Mentions
2008
McDermott's On the Subject "FDA Challenges Implied Outcomes Claims For Several ADHD Products: An Analysis" was featured in the October 17 issue of Health Lawyers Weekly.
Arnold I. Friede, Jason A. Lief, Robert B. Nicholas, Health, Life Sciences & Medical Devices, Life Sciences - FDA, Life Sciences - Health
McDermott's On the Subject "FDA Confirms Its View on Generic Drug Label Carve-Outs" was featured on October 9 in Health Law360.
Arnold I. Friede, Jason A. Lief, Robert B. Nicholas, Health, Life Sciences & Medical Devices, Life Sciences - FDA, Life Sciences - Health
Arnold Friede, Jason Lief and Robert Nicholas were mentioned in the September 2008 issue of Innsight Industry Newsletter in an article discussing the FDA's view on generic drug-label carve outs.
Arnold I. Friede, Jason A. Lief, Robert B. Nicholas, Health, Life Sciences & Medical Devices, Life Sciences - Health
Jason Lief, Arnold Friede and Robert Nicholas were mentioned in the August 22 issue of FDA'sWebview in an article regarding their recent On the Subject discussing the FDA' Camptosar® decision.
Arnold I. Friede, Jason A. Lief, Robert B. Nicholas, Health, Life Sciences - Health
2007
The November 12 issue of Chemical & Engineering News (C&EN) magazine included a letter to the editor from Jason Lief regarding the article from the September 17 edition concerning the new proposed patent legislation before congress as it relates to the justified concerns about the legislation and it's potential damaging effects in weakening patent protections.
Jason A. Lief, Intellectual Property, Media & Technology
Jason A. Lief was quoted in a June 7 article published by IPLaw360 regarding a provision of the U.S. Senate drug user fee bill that would lower the amount of market exclusivity that drug makers are awarded for pediatric testing of their drugs. Mr. Lief analyzed the switch from a six month exclusivity period to a three month exclusivity period by using a cost benefit analysis looking at the cost to society for the extra three months that is currently in place. "Is it too high given the benefits of some additional information on the clinical affects of a drug on children? Six months is worth it because they couldn't get people to do (the testing) without it," he said.
Jason A. Lief, Intellectual Property, Media & Technology, Life Sciences - IP
2006
Dennis Mondolino, Lisa Ferri, Michael Hurley and Jason Lief were mentioned in the 1/2006 issue of Juve Rechtsmarkt as new IP lawyers based in our New York office.
Lisa M. Ferri, Michael F. Hurley, Jason A. Lief, Dennis J. Mondolino, Intellectual Property, Media & Technology, Litigation - IP, Media & Tech
